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Purpose: To investigate the influence of macrolides as P-glycoprotein inhibitors on the level of intestinal 
absorption of digoxin.  
Methods: Jejunal segments of anaesthetized rats were cannulated and perfused by digoxin in 
phosphate buffered saline (PBS) at 37 °C in the presence or absence of macrolides (erythromycin and 
clarithromycin). Samples were obtained from outlet tubing at different time points and digoxin 
concentration assayed. The effective permeability of the drug was calculated after analyzing the 
samples using reverse-phase HPLC method.  
Results: Digoxin effective permeability was in the range of 0.24 ± 0.02 ×10-4 to 0.32 ± 0.06 ×10-4 
cm/sec for the control group. The macrolides significantly (p < 0.05) increased intestinal transport of 
digoxin, with digoxin in the presence of 150 μM of each macrolide in the range 0.42 ± 0.08 ×10-4 to 0.52 
± 0.07 ×10-4 cm/sec. However, no significant difference (p > 0.05) was observed between the effects of 
the two macrolides.  
Conclusion: The probable explanation for digoxin-macrolide interaction is inhibition of intestinal P-
glycoprotein-mediated efflux of digoxin which leads to increased digoxin intestinal absorption. 
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INTRODUCTION 
 
P-glycoprotein (P-gp), a 170-kilodalton 
plasma membrane protein, belongs to the 
ATP-binding cassette superfamily. This 
protein acts as an energy dependent 
transmembrane drug efflux pump which is 
localized in a wide range of tissues including 
enterocytes of the gastrointestinal tract [1].  
Studies in several species including rats have 
indicated that P-gp may play an important 
role in limiting drug absorption [2]. It limits the 
entry and/or accumulation of endogenous 
and exogenous P-gp substrates by active 
efflux. A large number of therapeutically and 
structurally disparate drugs are substrates for 
P-gp. Among these drugs digoxin has been 
well documented as a substrate for P-gp 
using in vitro and in vivo experiments [3, 4]. It 
is a cardiac glycoside which is widely used in 
the treatment of various heart conditions 
including atrial fibrillation, atrial flutter and 
congestive heart failure.  
 
There is a variation in the absolute 
bioavailability of digoxin and this represents 
an important issue in drug development and 
therapy. Its intra and inter-individual 
bioavailability were reported to be in the 
range of 40 - 90 % [5] and 50 - 85 % [5],  
respectively. These variations have been 
associated with oral formulation factors such 
as particle size, drug polymorphism, and 
aging of products [5].  However, the 
mechanism of absorption of digoxin from 
intestinal membrane and the underlying 
cause of its highly variable bioavailability 
have not been fully addressed.  
 
Macrolide antibiotics are used increasingly as 
first-line outpatient therapy for respiratory 
tract infections. Drug interactions involving 
these antibiotics include induction of hepatic 
metabolizing enzyme system and alteration 
of gastrointestinal flora [6]. There is evidence 
that certain macrolides, such as azithromycin 
and clarithromycin, are also inhibitors of 
apical drug efflux pump P-glycoprotein [7, 8]. 
However, the mechanism of macrolide-
digoxin interaction is not fully understood. 
Moreover, all available data for digoxin-
macrolide interaction are from case reports 
which leads to increased risk of digoxin-
induced toxicity, including arrhythmias, 
anorexia, altered color vision, and mental 
changes.  
 
To the best of our knowledge, there have 
been no controlled studies in vivo or in situ in 
this regard. Since macrolides used in 
reported cases were either erythromycin or 
clarithromycin, this study was aimed at 
assessing the effect of these macrolides on 
digoxin intestinal permeability. For this 
purpose, single-pass intestinal perfusion 
technique in anaesthetized rats was used. 
This approach is the most frequently used 
because it provides conditions closer to what 
to what obtains in humans following oral 






Digoxin (Boehringer Ingelheim, Germany), as 
well as erythromycin and clarithromycin 
(Elder Pharmaceutical Ltd, India) were kindly 
provided by Zahravi Pharmaceutical 
Company. Acetonitril and methanol were of 
high performance liquid chromatography 
(HPLC) grade and obtained from Merck 
(Germany). Phenol red was purchased from 
Sigma Chemical Co (USA). KH2PO4, 
NaH2PO4, Na2HPO4, H3PO4, NaOH, NaCl 
were purchased from Merck (Germany). 




A liquid chromatographic system (Beckman, 
USA) comprising of 126 gold solvent delivery 
module equipped with a Rheodyne (Cotati, 
California) injector and a variable wavelength 
ultraviolet 166 gold spectrophotometric 
detector (Beckman, USA) was used foe 
HPLC studies. The analytical column used for 
chromatographic separations was Shimpack 
VP-ODS 5 m 4.6 × 250 mm (Shimadzu, 
Japan) with a Shimpack VP-ODS 5 m 4.6 × 
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50 mm guard column (Shimadzu, Japan) for 
phenol red and C8 (4.6 × 150) Lichrosphere 
reverse phase select B column (Merck, 
Germany) for digoxin. The system’s Gold 
software was used for data acquisition while 
Gold nouveau software was used for data 




The mobile phase for digoxin was 26 %v/v of 
acetonitrile in water which was filtered 
through sintered glass filter P5 (1.0 - 1.6 µ, 
Winteg, Germany) and degassed in a 
sonicator (Liarre, Italy) under vacuum. The 
mobile phase was pumped in isocratic mode 
at a flow rate of 2 ml/min at ambient 
temperature. UV detection was accomplished 
at 218 nm and samples of 100 µl were 
injected using Hamilton injector syringe 
(Hamilton, Bonaduz, Switzerland) onto the 
column. For phenol red analysis, the mobile 
phase consisted of 45 %v/v of 0.5M KH2PO4 
and 55 %v/v methanol (adjusted to pH 2.6) 




In situ permeation studies were performed 
using established methods [9]  Male Wistar 
rats (200 - 250 g) were maintained on 12 h 
light-dark cycle and fasted 12 - 18 h before 
each experiment although drinking water was 
readily accessible. They were anaesthetized 
using an intraperitoneal injection of sodium 
pentobarbital (60 mg/kg) and placed on a 
thermostatted heated pad to maintain normal 
body temperature (38 - 39 °C). Upon 
verification of the loss of pain reflex, a midline 
abdominal incision was made. The small 
intestine was surgically exposed, 10 cm of 
jejunum ligated for perfusion and cannulated 
with plastic tubing (0.04 inch. i.d., 0.085 inch. 
o.d.). The ccannulated segment was rinsed 
with saline (37 oC) and attached to the 
perfusion assembly which consisted of a 
syringe pump (Palmer, UK) and a 60 ml 
syringe connected to it.  
 
The small intestine was gently handled during 
surgery in order to maintain an intact blood 
supply. The entire surgical area was then 
covered with saline-wet gauze (38  oC) and 
was kept warm with a heating lamp. Blank 
perfusion buffer (pH 7.2) was first infused for 
10 min followed by perfusion of test 
compounds at a flow rate of 0.2 ml/min for 90 
min. Four concentrations of digoxin in 
phosphate buffered saline were perfused in 
the absence and presence of P-gp inhibitors 
erythromycin and clarithromycin in separate 
groups of animals. Outlet samples were 
collected every 10 min in microtubes. The 
volume of sample for each time interval was 
2.0 ml. At the end of perfusion, the length of 
the segment was measured and the animal 
euthanitized by cardiac injection of saturated 
solution of KCl (345 g/L). Samples were 
stored at -20 oC until analysis.  
 
Preliminary experiments showed that no 
considerable adsorption of compounds on the 
tubing and syringe took place. Absorption or 
secretion of water was estimated by 
calculating the differences between inlet and 
outlet concentrations of phenol red (a non-
absorbable marker).  
 
The study was reviewed and approved by the 
institutional ethical review board of Tabriz 
University of Medical Sciences, Iran (ref no. 
8523) and adhered completely to the "Guide 
for the care and use of laboratory animals” 
[10]. 
 
Data treatment and statistics 
 
Effective permeability coefficients (Peff) were 
calculated after correcting outlet concen-
trations for water flux on the basis of the ratio 
of phenol red concentrations of perfusion 
buffer entered and left for each sampling 
point (10 min). Permeability values were 
calculated using Eq 1. 
rlCCQP inouteff 2]ln[  
where Q is the flow rate (0.2 ml/min), Cin and 
Cout the respective inlet and outlet 
concentrations that had been adjusted for 
water transport during perfusion, r is the 
……. (1) 
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radius of intestine (the most widely used 
estimate is 0.18 cm) and l is the length of the 
intestine measured after completion of 
perfusion.  
 
The length of the intestine was measured in 
situ placing a piece of string along the 
intestine and measuring the string with a 
ruler. Permeability values are given as mean 
± SEM. Statistical difference between the 
permeability of digoxin in the presence and 
absence of macrolides was evaluated by two-
tailed Student's t-test. (SPSS, 13 version, 
SPSS Inc., Chicago, USA). Statistical 
significance was set at p < 0.05.  
 
To evaluate the quantitative functional role of 
P-gp, intestinal efflux inhibition ratio (EIR), 
ratio of Peff due to P-gp-mediated efflux 
transport (Pp-gp) and passive permeability 
(PPD), were calculated. Pp-gp was calculated 
by subtracting Peff, control from Peff,inh while PPD 
is equal to Peff,inh. Thus the EIR is calculated 
according to Eq 2. 




During single-pass perfusion studies, steady 
state was reached about 40 min after the 
beginning of perfusion and was confirmed by 
plotting the ratio of the outlet to inlet 
concentrations versus time. The results are 
plotted in Fig 1. 
 
 
Fig 1: Plot of ratio of inlet and outlet 
concentrations (Cin/Cout) vs time for digoxin (20 
µ/ml) perfusion study. (n = 4, error bars represent 
SD) 
 
The mean effective permeability coefficient 
(cm/sec) of digoxin at concentrations of 5, 10, 
15 and 20 µM in perfusion solution were: 0.30 
± 0.01× 10-4, 0.29 ± 0.01× 10-4 , 0.32 ± 0.03 × 
10-4 and 0.24 ± 0.01 × 10-4, respectively.  In 
the presence of 150µM erythromycin as P-gp 
inhibitor in the perfusion buffer, at the above 
digixin concentrations, the permeability 
coefficient (cm/sec) values were: 0.49 ± 0.02 
× 10-4, 0.42 ± 0.02 × 10-4 , 0.48 ± 0.02 × 10-4 
and 0.42 ± 0.04 × 10-4, respectively (Fig 2). 
 
Fig 2: Intestinal permeability of digoxin in the 
absence and presence of P-gp inhibitors -  
erythromycin and clarithromycin (150 µM): □ 
control,  with erythromycin, ■ with 
clarithromycin;  values are mean ± SED  
 
When the experiments were carried out in the 
presence of clarithromycin, another efflux 
pump inhibitor, the effective permeability 
values at the above concentrations of digoxin 
were 0.46 ± 0.08 × 10-4 , 0.51 ± 0.07 × 10-4 , 
0.48 ± 0.06 × 10-4 and 0.52 ± 0.07 × 10-4 
cm/sec, respectively.   
 
Two-tailed Student’s t-test showed that the 
intestinal permeability of digoxin was 
significantly increased by erythromycin at all 
the four concentration of digoxin used (p < 
0.05). Similar results were obtained with 
clarithromycin as a P-gp inhibitor. However, 
there was no significant difference between 
the Peff values of digoxin in different 
concentrations indicating no concentration-
dependency for digoxin permeation. 
……. (1) 
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DISCUSSION 
 
To evaluate the possible role of P-gp in 
absorption of digoxin, a jejunal segment of rat 
small intestine was used. In the intestine, P-
gp is expressed in the brush-border 
membrane of enterocytes and acts as a first 
line of absorption barrier by limiting influx. 
Secondly, P-gp facilitates the efflux of its 
substrates from the blood to the intestinal 
lumen [11]. On the other hand, intestinal 
metabolism is also an important determinant 
of bioavailability. Most of the liver drug-
metabolizing enzymes are also present in the 
small intestine; however, the levels are 
generally much lower in the small intestine 
[12].  
 
Digoxin is metabolized in rat with 
approximately 60 % of plasma clearance 
being attributed to biotransformation by 
cytochrome P-450. Hepatic metabolism 
probably accounts for most of the 
biotransformation since in vitro incubation of 
digoxin with rat intestinal tissue showed that 
digoxin is not metabolized by rat enterocytes 
to any significant extent [12]. However, in 
another study with perfused rat small 
intestine, little metabolism in the small 
intestine was observed, and cytochrome P-
450 inducer treatment failed to change its 
metabolic profile [13]. These results suggest 
that the metabolism of digoxin is not 
dependent upon the cytochrome P-450 
system in the intestine.  
 
Therefore, in this study, the magnitude of 
possible P-gp-mediated drug interaction for 
digoxin and macrolides (erythromycin and 
clarithromycin) were compared at the 
absorption level. The single-pass intestinal 
perfusion model, with continuous perfusion of 
the lumen of an isolated segment of rat 
intestine with a solution of the drug, is 
particularly suitable for drugs with low 
absorption potential such as digoxin [2]. 
Since only a minor fraction of digoxin in the 
lumen is absorbed under control conditions, 
then an increase in the absorption rate is thus 
clearly evident from the corresponding 
decrease in the luminal level of digoxin 
relative to control experiments. The In the 
presence of erythromycin and clarithromycin, 
intestinal permeability of digoxin increased 
1.40 - 1.80 and. 1.54 - 2.18-fold, respectively.  
Therefore, it is clear that at least a part of the 
observed clinical interaction between 
erythromycin and digoxin is due to increased 
absorption level of the latter. In almost all 
previous case reports, digoxin toxicity was 
attributed to altered gastrointestinal flora 
resulting in decreased metabolism of digoxin 
to digoxin-reduced products (DRPs) by 
gastrointestinal flora [6]. Moreover, some 
animal studies show the unexpected contrary 
results [14, 15]. For example, Budinha et al 
[13] investigated the influence of verapamil 
(50 μM) as a P-gp inhibitor on digoxin 
transport using everted gut sac technique. In 
another study [15] using in situ circulated 
perfusion method, the effect of co-
administration of another P-gp inhibitor, 
quinidine, on digoxin absorption clearance 
was examined. Both studies [14, 15] reported 
a significantly decreased absorption of 
digoxin in the presence of efflux pump 
inhibitors.  
 
These results may be explained by the 
possible inhibitory roleeffect of verapamil and 
quinidine on organic anion transporter 
polypeptide (OATP) [5]. Digoxin is a 
substrate of OATP1B3 which was thought to 
be expressed only in the liver, but Glaeser et 
al [15] showed that it is also expressed in the 
intestine, and therefore, its inhibition results 
in reduced absorptive permeability of digoxin 
[16]. However, the results of the present 
study showed enhancement of digoxin 
intestinal absorption by inhibiting P-gp with 
macrolides which is in accordance with other 
previously reported studies [15,17]. Several 
pharmacokinetic studies in humans have 
indicated that P-gp inhibitors and inducers do 
not affect digoxin renal clearance [17]. 
Furthermore, increase in digoxin levels and 
toxicity have been observed only for orally 
co-administeration of digoxin and macrolides 
. Although it was suggested that erythromycin 
and clarithromycin had different potencies for 
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inhibition of P-gp [18], our results showed no 
significant difference between the effects of 
the macrolides which confirm the results of 
the study conducted by Tsutsumi et al. [19]      
 
Assuming complete P-gp inhibition by 
erythromycin, EIR for digoxin was found to be 
0.30 - 0.44, indicating that 30 – 44 % of 
passive transport of digoxin is attenuated by 
P-gp-mediated transport. Based on 
permeability data for digoxin in the presence 
and absence of clarithromycin, the EIR value 
is 0.35 - 0.54. According to previously 
published correlation between human and rat 
Peff values [9], the effective permeability 
coefficient for digoxin in human intestine is 
predicted to be more than 1.45×10-4 cm/sec. 
On the other hand,  the dose number (a 
criterion for solubility which is defined as the 
ratio of dose concentration to drug solubility) 
[20] of digoxin is 20.48; therefore, based on 
the previously published Biopharmaceutical 
Classification System (BCS) for drugs (which 
was derived from rat permeability and drug 
dose number) [21], digoxin can be classified 
as a BCS class IV drug, i.e., low permeability- 
low solubility drug (Do > 1, Peff (rat) > 4.02×10-5 
cm/sec) (Fig 3). Therefore, as it can be seen 
in Fig 3 digoxin lies under the cutoff for highly 
permeable drugs which was set to be 
5.09×10-5 cm/sec [21]. The intersections of 
dashed lines drawn at the cutoff points for 
permeability and dose/solubility ratio divide 
the plane in Fig. 3 into four explicitly defined 




Fig 3: Classification of drugs based on dose 
number and rat Peff values which were 
previousely reported by authors [21,22] . Digoxin 
is added to this system as a class IV drug. 
To confirm this finding, digoxin intrinsic 
dissolution rate (IDR) measurement is 
recommended which makes it possible to 
assess its category based on recently BCS 
[22]. Low and variable absorption for these 
drugs is anticipated because of the combined 
limitation of solubility and permeability. 
Formulation may improve the bioavailability 
of these drugs. However they are 
compromised by their poor intestinal 
membrane permeability. Strategies to 
improve both solubility and permeability 
should be worked out for these molecules, 
which may not be an easy task. However, 
obtaining this type of quality information will 
certainly improve drug design and help in 
optimizing candidates with "brick-like” 
properties. Consequently, the poor 
dissolution characteristics of digoxin dosage 





In this study, we found that erythromycin and 
clarithromycin enhanced the membrane 
permeability of digoxin in anaesthetized rats 
with no significant difference between their 
effects. Therefore, the most probable 
explanation for digoxin-macrolide interaction 
is inhibition of intestinal P-gp-mediated efflux 
of digoxin which leads to increased digoxin 
intestinal absorption. This finding should be 
considered when digoxin is prescribed 
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